Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

ICIC 2014 Tracking of the Mode of Action Landscape in Breast Cancer using Report and Visualization Tools

1.520 Aufrufe

Veröffentlicht am

Assessment of the “Mode of Action Landscape” for particular disease areas is of high interest for pharmaceutical companies. To enable identification of upcoming, established and vanishing modes of action over time and clinical phases it is crucial to have tools for integration and comparison of drug pipeline data from various sources, including informative visualizations of changes in the landscape.

The BizInt Smart Charts product family including VantagePoint - Smart Charts Edition (VP-SCE) enables these analyses and was therefore selected for evaluation. Data was integrated from different key drug pipeline databases, and the newly developed VP-SCE provided opportunities to use in-house data for normalization of important field content such as the highly diverse lists of “Mode of Action” generated by the pipeline databases. Using an example of pipeline data in the field of breast cancer we will show how the data was curated and processed to reach the final landscape, and how the programs can be applied in the most effective way. Examples of visualizations for facilitated decision-making will also be shown. To this end, our presentation will provide insight on the value of integrating and visualizing both external and internal data from drug pipelines employing these tools.

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

  • Gehören Sie zu den Ersten, denen das gefällt!

ICIC 2014 Tracking of the Mode of Action Landscape in Breast Cancer using Report and Visualization Tools

  1. 1. Tracking of the Mode of Action Landscape in Breast Cancer using Report and Visualization Tools Karen Jendro & Rebecca Ceder ICIC 2014, Heidelberg, Germany - October 14, 2014 Roche Pharma Research and Early Development, Roche Innovation Center Basel Roche Diagnostics GmbH, Penzberg
  2. 2. The Information Science Group in Penzberg Duties and Responsibilities Main duty Performing searches Patent searches Literature searches Sequence searches Business searches Enduser- Support for search tools Consultancy Information workflow Database development Evaluation of new sources and tools Support with text mining approaches = Karen‘s Job
  3. 3. The Data Science Group in Basel Duties and Responsibilities Main Activities Searching/Analyzing Imaging Literature Competitor NGS data Information Networks and Pathways Support Data Integration Target identification/ assessment Evaluation of new sources and tools Text-mining = Rebecca‘s job
  4. 4. Competitor Information @Roche Competitor Information: Our Definition  Competitor Information (CI) comprises secondary market research and pipeline data sources (=published public domain information) that are utilized to generate competitor landscapes (=overviews), to enhance the analysis of Roche’s activities, and thus to facilitate fact-based decision making regarding our drug pipeline portfolio.  CI is an important part of the whole Competitive Intelligence process at Roche
  5. 5. Competitor Information @Roche Background
  6. 6. Competitor Information @Roche Background
  7. 7. The Goal We want to create a visualization of the competitor information landscape that displays changes in the Mode of Action over time normalize visualize analyze changes
  8. 8. Major Questions to Address 1. How can we normalize the Mode of Action across different databases/information sources? 2. How can we visualize the Mode of Action Landscape in one figure to provide an overview? 3. How can we analyze and visualize the changes in the Mode of Action Landscape in a decision-making figure?
  9. 9. Import of the Breast Cancer Competitor Information Landscape into BizInt Smart Charts • The competitor information landscape from CIAP for Breast Cancer contains 4478 records from 3 different databases We want to normalize the “Mode of Action”
  10. 10. Normalization of the “Mode of Action” – Using VantagePoint-Smart Charts Edition Display of the “Mode of Action” Normalization of the “Mode of Actions using the Vantage-Point “Clean up” Function This process is partly automated, still requires manual “clean-up”
  11. 11. Normalization of the Mode of Action – - Using the Roche Terminology Service 272 records in total This process is fully automated
  12. 12. A bubble chart can be produced to overview the normalized Mode of Action Landscape Using Vantage Point-SCE Visualization of the Mode of Action Landscape - An Overview
  13. 13. Bubble Chart, Data from June 2014 Bubble Chart, Data from August Differences 2014 /Changes are hard to identify! Visualization of the Mode of Action Landscape -How Can We Determine the Changes?
  14. 14. Step 1: Data generation - BizInt Reference Rows • Essential: to have a function which compares the Modes of Action of each Substance, found in the Pipeline Databases => Usage of „Compare Columns“ in Reference Rows • Important: to get the additional as well as the vanished MoAs MoAs Substance 1 MoAs Substance 2
  15. 15. Step 2: Further processing in Visualization Tool • Import to Vantage Point-SCE • Selection of data to be visualized • Usage of Scipt for creation of bubble chart
  16. 16. Step 3: Result = Integrated Bubble Chart • Colors indicating increase, decrease, no change and both directions • Numbers indicating the count of Substances and arrows the direction of change
  17. 17. Complementary Examples where Data Comparison Approaches Can Play a Key Role • Tracking of geographical distribution of clinical trials over time - by comparing Countries by Trial Phase • Visualization of the shift towards new Indications for Drug classes, Drugs - by comparing Indications by Trial Phase • Change of Licensing availabilities for Drugs in certain indications - by comparing the Countries a license is available in • Identification of new modes of action a company is working on - by comparing MoAs by Trial Phase • And a lot of more ....
  18. 18. Summary And Take Home Messages • Most important: you need to have the appropriate thesaurus to clean up your data to get the most value out of it • The key to success was the “compare column” function in BizInt Reference Rows combined with the newly added Script for creating the “integrated bubble chart” • Not to forget: having fun with developing new ways to deal with data together with brilliant heads inside and outside of Roche!
  19. 19. Acknowledgements In alphabetical order • Dr Markus Bundschus (Roche) • Matt Eberle (BizInt) • Dr Barbara Endler-Jobst (Roche) • Dr Werner Klaus (Roche) • Dr Pascal Kuner (Roche) • Dr Martin Romacker (Roche) • Diane Webb (BizInt) • John Willmore (BizInt) • VantagePoint Smart Charts Edition
  20. 20. Doing now what patients need next